Viewing nowGlivec 20 mg (Memantine Hydrochloride)
Memantine Hydrochloride 20mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

MFDS item code 202500349 · Approved 2025.02.17 · Insurance code 694004520
Treatment of moderate to severe Alzheimer’s disease
This medication is used to improve cognitive function and alleviate symptoms in patients with moderate to severe Alzheimer's disease.
Treatment must be initiated by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia, and only if a caregiver is available to regularly check that the patient is taking the medicine. The diagnosis should be made in accordance with currently accepted guidelines. The clinical benefit of this medicine and the patient’s tolerability of treatment should be reassessed regularly. This medicine is administered orally once daily, at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (Days 1–7): Administer 5mg once daily for 7 days. Week 2 (Days 8–14): Administer 10mg once daily for 7 days. Week 3 (Days 15–21): Administer 15mg once daily for 7 days. From Week 4 onward: Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults Based on clinical data, the recommended dose for patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose escalation schedule. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. 4. Patients with hepatic impairment No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine to these patients.
This medication should not be used in patients who are allergic to any component of this drug, those with severe liver impairment, or those with significant renal impairment. It should be used cautiously in patients with epilepsy or those who have a history of seizures, or in conditions where seizures may easily occur. Additionally, concomitant use with NMDA receptor antagonists such as amantadine, ketamine, or dextromethorphan may increase central nervous system side effects, so it is advisable not to use them together. Care should be taken when using this medication in situations where urine acidity is elevated or in patients drinking large amounts of alkaline beverages, and those with specific urinary tract infections should be closely monitored. Safety data is insufficient for patients with heart disease or uncontrolled hypertension, so careful administration is required. While taking this medication, side effects such as dizziness, headache, constipation, drowsiness, and hypertension may occur; if symptoms are severe, consult a healthcare professional. There may be interactions with other medications, so caution is advised when taken with levodopa, dopamine agonists, anticholinergics, barbiturates, antipsychotics, and skeletal muscle relaxants. Pregnant women or those who may become pregnant should only use this drug when the benefits outweigh the risks, as it may affect the fetus. If breastfeeding, it is recommended to discontinue nursing as this medication may be transmitted through breast milk. The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age. In case of overdose, symptoms such as confusion, drowsiness, dizziness, hallucinations, seizures, vomiting, and diarrhea may occur, and immediate medical attention is required. This medication may impair reaction speed and concentration, so special attention should be paid when driving or operating machinery. Finally, this medication should be kept out of the reach of children, and transferring it to another container should be avoided as it may negatively affect quality.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is room temperature between 1°C and 30°C.
Pink oval film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 20mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.